dr. weber on biomarker data from checkmate-238 for melanoma
Published 4 years ago • 150 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:17
dr. weber on checkmate-238 compared to other trials in melanoma
-
0:56
dr. weber on checkmate-238 for melanoma
-
1:50
dr. weber discusses updated data for checkmate-238
-
1:05
dr. weber on rationale for the checkmate-238 trial in melanoma
-
1:44
dr. weber on the updated analysis of the checkmate-238 trial in melanoma
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
5:30
jeffrey s weber, asco 2018 – resected stage iii melanoma and the checkmate 238 trial
-
1:58
dr. weber on duration of checkpoint inhibitor therapy in melanoma
-
2:25
dr. weber on discontinuing immunotherapy in melanoma
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
2:18
dr. jeffrey weber on checkmate-064 trial for advanced melanoma
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
0:58
impact of checkmate-238 results for patients with melanoma
-
2:56
encouraging phase 3 checkmate 238 data: adjuvant nivolumab in resected stage iii/iv melanoma
-
1:22
dr. weber on nivolumab versus chemotherapy in advanced melanoma
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
1:05
dr. weber on the future of checkpoint inhibitors in melanoma
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma